These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 28653421)
21. Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery. Marchesi F; Mengarelli A Curr Med Chem; 2016; 23(21):2217-29. PubMed ID: 27183986 [TBL] [Abstract][Full Text] [Related]
22. A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization. Manko J; Walter-Croneck A; Jawniak D; Grzasko N; Gorska-Kosicka M; Cioch M; Dmoszynska A Pharmacol Rep; 2014 Apr; 66(2):239-42. PubMed ID: 24911076 [TBL] [Abstract][Full Text] [Related]
23. Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122). Jung EH; Byun JM; Shin DY; Do YR; Jo JC; Lee SM; Yoon SS Cancer Med; 2023 Apr; 12(8):9186-9193. PubMed ID: 36951655 [TBL] [Abstract][Full Text] [Related]
25. Lenograstim 5 µg/kg is not superior to biosimilar filgrastim 10 µg/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study. Marchesi F; Vacca M; Giannarelli D; Ipsevich F; Pandolfi A; Gumenyuk S; Renzi D; Palombi F; Pisani F; Romano A; Spadea A; Papa E; Canfora M; Pierelli L; Mengarelli A Transfusion; 2018 May; 58(5):1143-1148. PubMed ID: 29446445 [TBL] [Abstract][Full Text] [Related]
26. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. Bhamidipati PK; Fiala MA; Grossman BJ; DiPersio JF; Stockerl-Goldstein K; Gao F; Uy GL; Westervelt P; Schroeder MA; Cashen AF; Abboud CN; Vij R Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783 [TBL] [Abstract][Full Text] [Related]
27. Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience. Islami MM; Khan MA; Aseeri MA; Alshamrani MA; Alnatsheh A; Alamoudi S; Alzahrani AA Ann Transplant; 2023 Mar; 28():e938585. PubMed ID: 36864713 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim. Marchesi F; Terrenato I; Papa E; Tomassi M; Falcucci P; Gumenyuk S; Palombi F; Pisani F; Renzi D; Romano A; Spadea A; Regazzo G; Rizzo MG; De Rienzo M; Ripellino C; Sgromo S; Viggiani C; Ponte E; Kayal R; Cordone I; Foddai ML; Mengarelli A Ann Hematol; 2024 Mar; 103(3):947-956. PubMed ID: 38189833 [TBL] [Abstract][Full Text] [Related]
29. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF. Schmitt M; Hoffmann JM; Lorenz K; Publicover A; Schmitt A; Nagler A Vox Sang; 2016 Aug; 111(2):178-86. PubMed ID: 27509033 [TBL] [Abstract][Full Text] [Related]
30. Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Orciuolo E; Buda G; Marturano E; Mauro E; Milone G; Cangialosi C; Di Renzo N; Pastore D; Specchia G; De Paolis MR; Mazza P; Pietrantuono G; Petrini M Leuk Res; 2011 Jul; 35(7):899-903. PubMed ID: 21134693 [TBL] [Abstract][Full Text] [Related]
31. Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation. Schmitt M; Publicover A; Orchard KH; Görlach M; Wang L; Schmitt A; Mani J; Tsirigotis P; Kuriakose R; Nagler A Theranostics; 2014; 4(3):280-9. PubMed ID: 24505236 [TBL] [Abstract][Full Text] [Related]
32. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
33. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation. Elayan MM; Horowitz JG; Magraner JM; Shaughnessy PJ; Bachier C Biol Blood Marrow Transplant; 2015 Nov; 21(11):1921-5. PubMed ID: 26033279 [TBL] [Abstract][Full Text] [Related]
34. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma. Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986 [TBL] [Abstract][Full Text] [Related]
35. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278 [TBL] [Abstract][Full Text] [Related]
36. What is the role of biosimilar G-CSF agents in hematopoietic stem cell mobilization at present? Korkmaz S; Altuntas F Transfus Apher Sci; 2017 Dec; 56(6):795-799. PubMed ID: 29153313 [TBL] [Abstract][Full Text] [Related]
37. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of a conversion from filgrastim to filgrastim-sndz in stem cell transplant patients undergoing mobilization. Curry LD; Anders B; Dressler EV; Kennedy L J Oncol Pharm Pract; 2021 Jun; 27(4):871-876. PubMed ID: 32686616 [TBL] [Abstract][Full Text] [Related]
39. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. Zappasodi P; Nosari AM; Astori C; Ciapanna D; Bonfichi M; Varettoni M; Mangiacavalli S; Morra E; Lazzarino M; Corso A Transfusion; 2008 May; 48(5):857-60. PubMed ID: 18248573 [TBL] [Abstract][Full Text] [Related]
40. Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network. Marchesi F; Cerchiara E; Dessanti ML; Gumenyuk S; Franceschini L; Palombi F; Pisani F; Romano A; Spadea A; Pupo L; Annibali O; La Malfa A; Arcese W; Mengarelli A Br J Haematol; 2015 Apr; 169(2):293-6. PubMed ID: 25371286 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]